OUR STORY
Rewriting the script to outmatch disease
Founded on groundbreaking research in E3 ligases, Nurix has evolved into a targeted protein degradation powerhouse, leveraging its experience and expertise to translate the science of degradation into clinical advances.
LEADERSHIP
Championing breakthroughs for patients
With world-renowned experts in E3 ubiquitin ligase regulation and seasoned biotech executives, Nurix is accelerating development of medicines based on targeted protein degradation.
PARTNERING
Strategic collaborations
We’ve forged strategic alliances with industry leaders like Gilead Sciences, Sanofi, and Pfizer, expanding our reach and impact in drug discovery and development.
